In this paper, the authors describe a new metric to “score” the post-merger likelihood of parallel accommodating conduct.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...

